LAUSR

Objectives: this study was to examine the antihypertensive effects of Garcinia mangostana Linn extract consumption in humans Methods: A randomized, Single-blind, placebo-controlled clinical trial was conducted in 66 pre- and mildly hypertensive adults which were determined based on JNC VII, age 50–70 y, Patients use combination of antihypertension drug were excluded. The patients were divided into two group. One group given 2520 mg/day Garcinia mangostana Linn extracts in 3 divided dose for 90 days and the other group given placebo. A standardized method was used to measure BP at baseline and monthly intervals. The parameters were Nitrit Oxide (NO), IL-1,IL-6, measured at baseline and after 90 day's of treatment Results: At 90 days, Garcinia mangostana Linn extracts lowered systolic BP (SBP) compared with placebo (−22.82 ± 11.4 vs. − 10 ± 16.0 mmHg; P = 0.007). Diastolic BP was also lower, although this change did not differ from placebo (−8.7 ± 11.2 vs. − 5,4 ± 9.3 mmHg; P = 0.21). The change in heart rate was significance compared with placebo (−6.13 ± 9,6/min vs. 1,43 ± 3.04/min; P = 0.021). The change in mean arterial pressure was significance compared with placebo (−13,47 ± 12,01 vs. − 7,03 ± 9.7 mmHg; P = 0.028). Interestingly, we found that there was a significance decreasing in Nitric Oxide (NO) compared with placebo (−8.23 ± 14,9 uM vs. 4,3 ± 14.51 uM; P = 0.002). We found that The plasma IL-6 and IL-1 concentration was significantly lower compared with placebo (−95.86 ± 107,3 pg/ml vs. 37,87 ± 149,89 pg/ml; P = 0.000; − 11.26 ± 16,46 pg/ml vs. 9.59 ± 13.65 pg/ml; P = 0.000, respetively). Conclusion: These results suggest that consumption of Garcinia mangostana Linn extract significantly reduce systolic blood pressure in pre- and mildly hypertensive adults